What's the typical lurbinectedin dosage for infants?

There isn’t a published, approved dosing regimen for infants or very young children for lurbinectedin. Lurbinectedin is approved for adults with relapsed small cell lung cancer, and pediatric dosing (including infants) has not been established. It is not routinely used in infants outside of a clinical trial.

If you’re asking about adult dosing (for context):
- Typical adult regimen is 2.0 mg/m^2 given as a one-hour IV infusion on Day 1 of a 21-day cycle, continued until disease progression or unacceptable toxicity.

Important points:
- Use in infants or children would require a clinical trial or pediatric-specific guidance; dosing cannot be extrapolated reliably from adults.
- Lurbinectedin can cause serious toxicities (neutropenia, thrombocytopenia, liver enzyme elevations, fatigue, etc.), so pediatric use would be tightly controlled under a trial.

If this is for an infant patient:
- please consult a pediatric oncologist or a cancer center with clinical trials. They can tell you if any pediatric studies are available and what dosing would be appropriate in that setting.

If you want, I can help you find current clinical trials or official labeling references, or provide general safety information.